Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease

Bookmark and Share
Published: 21 Dec 2021
Views: 437
Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Komal Jhaveri speaks to ecancer about the latest updates from the SUMMIT trial. This trial investigates neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease.
Dr Jahveri talks about the background and methodology of the trial before going on to report the results.

She says that the combination of neratinib + fulvestrant + trastuzumab demonstrated encouraging clinical activity in heavily pre-treated HER2-mutant, HR+, HER2-non-amplified mBC, including patients who had previously received either fulvestrant and/or CDK4/6 inhibitor-based therapies.

While the rate of grade 3 diarrhoea was higher than that observed with single-agent neratinib in SUMMIT, this was manageable through loperamide prophylaxis, and no patients discontinued study treatment due to diarrhoea.

She concludes by mentioning how these results can impact the future treatment of breast cancer.